Nuvectis Pharma Inc（NVCT）财务数据NVCTNuvectis Pharma Inc

Evaluating the bottom line, Nuvectis Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -233.30%, provide a clear picture of how effectively NVCT converts its operational activities into shareholder value.

In the context of the broader market, NVCT competes directly with industry leaders such as AVTX and PHAR. With a market capitalization of $672.14M, it holds a significant position in the sector. When comparing efficiency, NVCT's gross margin of N/A stands against AVTX's N/A and PHAR's N/A. Such benchmarking helps identify whether Nuvectis Pharma Inc is trading at a premium or discount relative to its financial performance.

Nuvectis Pharma has reported a net loss of $7 million for Q2 2026, up from $6.3 million in the same period of 2025, indicating challenges in managing costs. The company has a current ratio of 1.68, suggesting it may face liquidity issues in the near term.